



News Release

BD Biosciences Pharmingen Licenses Technology from Stanford University to Advance Proteomics and Cell Analysis Research

San Jose, CA, December 17, 2002—BD Biosciences, a business segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today it has licensed a key technology and pending intellectual property developed by Dr. Garry Nolan and Dr. Omar Perez of Stanford University, Palo Alto, California. The technology, *Methods and Composition for Detecting the Activation State of Multiple Proteins in Single Cells*, will enable scientists to use flow cytometry to detect the modified state of proteins within a signal transduction pathway. These signal transduction, or cellular, pathways are involved in a variety of metabolic functions and diseases and are of great interest to academic and pharmaceutical scientists.

“We selected BD Biosciences for this collaboration largely because of its proven track record in commercializing antibodies, and its unique position in the proteomics and cell analysis markets. We feel that having a trusted and established partner for this important technology will be critical to the advancement of science and technology in these areas as well as to the understanding of how specific proteins and cell types are involved in disease states,” said Dr. Garry Nolan of Stanford University.

Cellular pathways often involve several different proteins, which can be changed as one protein interacts with another. Using this technology, BD Biosciences will attempt to develop and commercialize unique tools to study the interaction of proteins within a given pathway. Insight into these pathways could lead to a more complete understanding of their effect on a variety of disease states such as cancer, AIDS, and other immune system disorders.

“We believe this technology allows us to combine our expertise in flow cytometry and our antibody portfolio to create new multiparameter assays to study cellular pathways in the rapidly growing field of proteomics,” explained Kip Miller, Vice President and General Manager of BD Biosciences Pharmingen. “Dr. Nolan’s laboratory is at the forefront of research in this field and this relationship strengthens our position as a leading provider of unique methods in the field of flow cytometry.”

###

Notes to the Media

About BD: BD (Becton, Dickinson and Company) is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, and the general public. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment, and diagnostic products.

About BD Biosciences: A business segment of BD, BD Biosciences (www.bdbiosciences.com) is one of the world’s largest businesses supporting the life sciences and is organized into four principal groupings: Clontech, Discovery Labware, Immunocytometry Systems, and Pharmingen. BD Biosciences provides high-quality products and services to accelerate discovery and diagnosis in the life sciences.

Media Contacts

Lisa English
Strategic Communications, BD Biosciences
408-954-2339 / 408-954-2009 (fax)
Lisa_English@bd.com

Tony Ward
Director Marketing, BD Biosciences Pharmingen
858-812-8862 / 858-812-8889 (fax)
Tony_Ward@bd.com

This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, products and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; uncertainties of litigation; BD's ability to achieve sales and earnings forecasts, which are based on sales volume and product mix assumptions, to achieve its cost savings objectives, and to achieve anticipated synergies and other cost savings in connection with acquisitions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; changes in interest or foreign currency exchange rates; delays in product introductions; and changes in health care or other governmental regulation, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. BD does not intend to update any forward-looking statements. [make sure most recent version when BD CC/IR does review]